GPR55
GPR55 is a lysophosphatidylinositols and cannabinoids receptor. It is involved in various signaling cascade and plays a role in neuropathic/inflammatory pain, cancer and metabolic regulation etc.
Products Related to GPR55(11)
- GC16103OleylethanolamideCAS: 111-58-0Purity: >99.50%
Oleylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
- GC35339AnandamideCAS: 94421-68-8Purity: >98.00%
Anandamide, an endocannabinoid derived from arachidonic acid-containing membrane lipids, exerts its actions by binding and activating CB1 and CB2 receptors (cannabinoid receptors 1 and 2) and the vanilloid transient receptor potential vanilloid 1 (TRPV1) receptor.
- GC35694CID 16020046CAS: 834903-43-4Purity: >99.50%
CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC50 of 0.15 μM. CID 16020046 inhibits GPR55-mediated Ca2+ signaling and GPR55-mediated ERK1/2 phosphorylation. CID 16020046 reduces wound healing in endothelial cells and is involved in the regulation of platelet function.
- GC69771PSB-SB-487CAS: 1399049-81-0Purity: >99.00%
PSB-SB-487 is an effective GPR55 antagonist and CB2 agonist, with an IC50 of 0.113 µM for GPR55 and a Ki of 0.292 µM for human CB2. PSB-SB-487 can be used to study diabetes, Parkinson's disease, neuropathic pain, and cancer.
- GC73616GPR55 agonist 4CAS: 3006105-55-8Purity: >98.00%
GPR55 agonist 4 (Compound 28) is a GPR55 agonist (EC50: 131 nM, and 1.41 nM for hGPR55 and rGPR55).
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC12728 | Abn-CBD | 22972-55-0 | >98.00% | |
GPR55 cannabinoid receptor agonist | ||||
| GC13513 | O-1602 | 317321-41-8 | >98.00% | |
GPR55 cannabinoid receptor agonist | ||||
| GC14026 | ML-193 | 713121-80-3 | >95.00% | |
GPR55 antagonist | ||||
| GC16103 | Oleylethanolamide | 111-58-0 | >99.50% | |
Oleylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis. | ||||
| GC17777 | Palmitoylethanolamide | 544-31-0 | >98.00% | |
GPR55 agonist | ||||
| GC35339 | Anandamide | 94421-68-8 | >98.00% | |
Anandamide, an endocannabinoid derived from arachidonic acid-containing membrane lipids, exerts its actions by binding and activating CB1 and CB2 receptors (cannabinoid receptors 1 and 2) and the vanilloid transient receptor potential vanilloid 1 (TRPV1) receptor. | ||||
| GC35694 | CID 16020046 | 834903-43-4 | >99.50% | |
CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC50 of 0.15 μM. CID 16020046 inhibits GPR55-mediated Ca2+ signaling and GPR55-mediated ERK1/2 phosphorylation. CID 16020046 reduces wound healing in endothelial cells and is involved in the regulation of platelet function. | ||||
| GC44217 | ML-184 | 794572-10-4 | >98.00% | |
GPR55 is a G protein-coupled receptor that is weakly activated by some cannabinoids (CBs) at nM concentrations but displays a 5- to 10-fold greater stimulation in response to 1 μM lysophosphatidylinositol (LPI). | ||||
| GC69771 | PSB-SB-487 | 1399049-81-0 | >99.00% | |
PSB-SB-487 is an effective GPR55 antagonist and CB2 agonist, with an IC50 of 0.113 µM for GPR55 and a Ki of 0.292 µM for human CB2. PSB-SB-487 can be used to study diabetes, Parkinson's disease, neuropathic pain, and cancer. | ||||
| GC73616 | GPR55 agonist 4 | 3006105-55-8 | >98.00% | |
GPR55 agonist 4 (Compound 28) is a GPR55 agonist (EC50: 131 nM, and 1.41 nM for hGPR55 and rGPR55). | ||||
| GC80865 | Anandamide- 15 N | - | >99.50% | |
Anandamide - 15 N (AEA- 15 N) is the 15 N-labeled Anandamide. | ||||